Boehringer Ingelheim International Gmbh

Scott Godfrey

Jonathan Coffman

Raquel Orozco

Jens Holger Vogel

Jeff Goby

Robert L Fahrner

Jeffrey Richard Salm

Marcus Andre Fiadeiro

Samantha Wang

Stephanie Parker

Robert E Kottmeier

Joseph K McLaughlin

Cameron Lee Bardliving

Lisa Sawicki

Aaron Thomas Kwong

Matthew Robert Brown

Integrated systems and methods for the manufacturing of recombinant proteins in mammalian cells are provided. The systems and methods include a single-use bioreactor (SUB), a tangential flow filtration system, a column chromatography skid, a tankless hold, a virus inactivation plug flow reactor, and pumps.

Integrated and continuous recombinant protein manufacturing

A viral inactivation device including at least one continuous viral inactivation reactor having an inlet, an outlet, and a tubular flow path. The tubular flow path includes a set of alternating turns that form a serpentine pattern between the inlet and the outlet.

Continuous flow reactor for low pH viral inactivation

The present invention provides improved bioprocessing systems and methods for cell culture using the improved bioreactors, e.g., batch-fed or perfusion bioreactor cell culture systems for production of monoclonal or bi-specific antibodies, which are modified to include one or more membrane gas transfer modules in place of a sparger- or microsparger-based aeration systems to better regulate the levels of critical gases in a bioreactor cell culture, e.g., the dissolved levels of Oand CO, even at high cell densities, without subjecting the cells to bubble-burst associated cell death.

Method for membrane gas transfer in high density bioreactor culture

The subject technology relates to a cell retention device and method for use in a perfusion cell culture system where the cell retention device includes a hollow-fiber filter having an average pore size ranging from about 0.5 to about 20 μm and having the ability to operate under perfusion cell culture conditions for up to 35 days without being clogged or losing its product sieving ability by more than 20%.

Cell retention device and method

Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.

Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product

Growing community of inventors

Pleasanton, CT, United States of America

Scott Godfrey